The information described in the publication is an update in influenza A viruses’ activity in the United States from October 1st to November 25, 2017, in which the majority of cases diagnosed were influenza A (H3N2) activity in the United States from October 1st to November 25, 2017.
According to the MMWR, the influenza virus was low during the month of October; however, it was seeing an increment in cases during the month of November 2017. Being informed, that the indicators for this viral infection were higher for that time of the year. Hence, it has been difficult to predict if this type of influenza A H3N2 will be the predominant during this season according to the viral surveillance done by the WHO, and the National Respiratory and Enteric Virus surveillance system laboratories. Being reported a total of 3,723 or 73.
4% specimens that tested positive for influenza A, compared to 1,347 or 26.6% from positive samples tested for influenza B during this period and from patients from all age groups.This information has great significance for public health since epidemiologists can follow the trends of an epidemy and its patterns, in order to identify the influenza virus and its variants; to reduce the onset of cases reported positive for influenza.
Also, to prevent the spread of the viruses, and to develop the necessary measurements to stop the incidence, and the mortality rates from the influenza virus during the flu season.Public health professionals might utilize the information in practice, by studying and analyzing the data provided to control and prevent the spread of the influenza viruses; by monitoring the cases diagnosed positive. Being that the influenza virus is a notifiable infectious disease, it is required to be notified by medical practitioners to the local and state health departments and the CDC. Public health professionals also might use this information to implement the vaccination with the development of preventive interventions to reduce the number new cases and to avoid the probabilities of becoming infected with the influenza viruses and to evaluate vaccine and treatment effectiveness.
Also, to track how the antivirals are working in early treatment, on patients who are newly diagnosed or suspected that had acquired the virus. Also, to evaluate if the cases are severe or complicated and require hospitalization; as well as if the virus is progressive, and to monitor the most susceptible populations and the mortality rates in these populations.